Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) had its target price increased by equities researchers at JPMorgan Chase & Co. from $79.00 to $81.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential downside of 11.33% from the stock’s current price.
Several other equities analysts have also recently commented on HALO. Wedbush set a $130.00 target price on Halozyme Therapeutics in a research note on Friday. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $95.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Friday, November 6th. Stifel Nicolaus set a $130.00 price target on shares of Halozyme Therapeutics in a research note on Friday, October 16th. Leerink Partners cut shares of Halozyme Therapeutics from an “outperform” rating to a “hold” rating and upped their price target for the company from $110.00 to $117.00 in a report on Friday, November 6th. Finally, Citizens Jmp increased their price objective on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the company a “market outperform” rating in a research note on Friday, November 6th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $110.17.
Check Out Our Latest Stock Analysis on Halozyme Therapeutics
Halozyme Therapeutics Trading Down 1.8%
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. The firm had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. During the same quarter last year, the firm earned $1.72 EPS. Halozyme Therapeutics’s quarterly revenue was up 39.1% on a year-over-year basis. Sell-side analysts forecast that Halozyme Therapeutics will post 8.34 EPS for the current fiscal year.
Insider Activity
In other Halozyme Therapeutics news, Director Matthew L. Posard sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 18th. The stock was sold at an average price of $96.43, for a total transaction of $482,150.00. Following the transaction, the director owned 48,609 shares of the company’s stock, valued at $4,687,365.87. This trade represents a 9.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $98.38, for a total value of $1,967,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $75,534,196.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 149,226 shares of company stock valued at $15,744,643. 2.50% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Halozyme Therapeutics
Institutional investors have recently made changes to their positions in the company. American Century Companies Inc. raised its position in shares of Halozyme Therapeutics by 4.8% during the 3rd quarter. American Century Companies Inc. now owns 112,764 shares of the biopharmaceutical company’s stock valued at $12,449,000 after acquiring an additional 5,145 shares in the last quarter. Kestra Advisory Services LLC lifted its stake in Halozyme Therapeutics by 47.9% during the third quarter. Kestra Advisory Services LLC now owns 14,793 shares of the biopharmaceutical company’s stock worth $1,633,000 after purchasing an additional 4,788 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in Halozyme Therapeutics in the third quarter worth $776,000. Zacks Investment Management boosted its holdings in Halozyme Therapeutics by 2.6% in the third quarter. Zacks Investment Management now owns 33,464 shares of the biopharmaceutical company’s stock worth $3,694,000 after purchasing an additional 837 shares during the period. Finally, Integrated Wealth Concepts LLC boosted its holdings in Halozyme Therapeutics by 15.2% in the third quarter. Integrated Wealth Concepts LLC now owns 4,643 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 612 shares during the period. 97.79% of the stock is currently owned by institutional investors.
Key Headlines Impacting Halozyme Therapeutics
Investors following HALO have been watching these headlines:
- Positive Sentiment: HC Wainwright reaffirmed its buy rating and set a $130 price target, suggesting substantial upside from the cited share price. HC Wainwright ratings
- Neutral Sentiment: JPMorgan raised its target to $81 from $79 but maintained a neutral rating; the new target is below the cited share price, signaling a more cautious view. JPMorgan ratings
- Negative Sentiment: A German court overturned the preliminary injunction that had blocked Merck from offering its subcutaneous Keytruda product in Germany. Halozyme says it will pursue a permanent patent case, but the ruling removes an immediate barrier to Merck’s launch and adds uncertainty to the dispute’s potential commercial impact. Report on German court ruling
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
Further Reading
- Five stocks we like better than Halozyme Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
